Skip to main content
PHVS
NASDAQ Life Sciences

Pharvaris' CHAPTER-3 Hits Primary Endpoint: 83% Attack Reduction in HAE Prophylaxis

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$40
Mkt Cap
$2.463B
52W Low
$20.65
52W High
$38.13
52W Position info
94% above low
Off High info
at 52W high
Rel. Volume info
0.9× avg
Market data snapshot near publication time

PHVS sits 94% above its 52-week low of $20.65.

Summary

Pharvaris announced positive topline data from its CHAPTER-3 pivotal Phase 3 study of deucrictibant XR for prophylaxis of HAE attacks. The primary endpoint and all secondary efficacy endpoints were met with statistical significance. Treatment reduced mean monthly attack rate by 83% (p<0.0001) across all HAE types, and by 87% in the HAE Type 1/2 subgroup. Protection was early-onset within the first week and sustained through 24 weeks. Deucrictibant XR was well tolerated with no treatment-related serious adverse events. This is the first and only prophylaxis Phase 3 study to evaluate all three types of HAE. The company plans to submit an NDA for prophylaxis in H1 2027, with CREAATE Part 1 topline data for AAE-C1INH expected in Q1 2027. This follows the FDA's acceptance of the NDA for deucrictibant IR (on-demand) in July 2026, positioning Pharvaris for two potential launches. The stock is trading near its 52-week high, reflecting high expectations that these results now validate.

At the time of this announcement, PHVS was trading at $40.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.5B. The 52-week trading range was $20.65 to $38.13. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

PHVS - Latest Insights

PHVS
Nov 12, 2026, 6:51 AM EST
Filing Type: 6-K
Importance Score:
7
Price at Filing: $34.18
Real-time Price: $31.55 info
Change: -$2.63 (-8%) info
Market Cap: $2.215B info
PHVS
Oct 08, 2026, 6:35 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $30.68
Real-time Price: $31.55 info
Change: +$0.870 (+3%) info
Market Cap: $2.215B info
PHVS
Sep 17, 2026, 5:27 PM EDT
Filing Type: 144
Importance Score:
7
Price at Filing: $37.96
Real-time Price: $31.55 info
Change: -$6.41 (-17%) info
Market Cap: $2.215B info
PHVS
Sep 17, 2026, 5:27 PM EDT
Filing Type: 144
Importance Score:
7
Price at Filing: $37.96
Real-time Price: $31.55 info
Change: -$6.41 (-17%) info
Market Cap: $2.215B info
PHVS
Sep 08, 2026, 9:00 AM EDT
Filing Type: 6-K
Importance Score:
9
Price at Filing: $42.40
Real-time Price: $31.55 info
Change: -$10.85 (-26%) info
Market Cap: $2.215B info